Stockscreener 앱 받기
153.75
1.18%
1.79
시간 외 거래:
154.22
0.47
+0.31%
전일 마감가:
$151.96
열려 있는:
$152
하루 거래량:
424.54K
Relative Volume:
0.45
시가총액:
$15.33B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
52.12
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+1.43%
1개월 성능:
+7.37%
6개월 성능:
+23.47%
1년 성능:
+20.36%
1일 변동 폭
$151.01
$153.75
1주일 범위
$149.58
$154.35
52주 변동 폭
$84.23
$157.67
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
153.75 | 15.15B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
120.41 | 54.02B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.28 | 45.21B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.53 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.41 | 31.93B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
485.21 | 20.71B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Institutional Moves & Weekly High Potential Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock remains top ratedMarket Trend Summary & Daily Technical Forecast Reports - Newser
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockTrade Ideas & Verified Stock Trade Ideas - Newser
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy lists2025 Volume Leaders & Fast Entry Momentum Alerts - Newser
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing - MarketScreener
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile - simplywall.st
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusQuarterly Profit Report & Growth Focused Entry Reports - Newser
Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating - MarketScreener
(NBIX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation Following New Narrative Review on VMAT2 Therapies - simplywall.st
Neurocrine Bio. stock jumps as rival drug faces modest Medicare price cut - Investing.com Canada
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication - Yahoo Finance
Published on: 2025-11-28 13:55:28 - BỘ NỘI VỤ
Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now - sharewise.com
Does Neurocrine Biosciences’ 9.8% Jump Signal a New Valuation Opportunity in 2025? - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences Insider Sold Shares Worth $2,150,513, According to a Recent SEC Filing - MarketScreener
Neurocrine Biosciences Director Sells 15,000 Shares - TradingView
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut - Investing.com Australia
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut By Investing.com - Investing.com South Africa
Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout - BioWorld MedTech
Neurocrine Extends Eiry W. Roberts’ Employment Term - The Globe and Mail
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN
Neurocrine's collaboration for pipeline and market expansion - MarketScreener
[8-K] NEUROCRINE BIOSCIENCES INC Reports Material Event | NBIX SEC FilingForm 8-K - Stock Titan
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - Markets Financial Content
Neurocrine review highlights key differences between tardive dyskinesia drugs - Indian Pharma Post
Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments By Investing.com - Investing.com Canada
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Neurocrine Biosciences Inc Stock Analysis and ForecastEarnings Forecast Updates & High Yield Investment Portfolio - earlytimes.in
A Look at Neurocrine Biosciences (NBIX) Valuation After Setback in Depression Drug Trial - simplywall.st
What analysts say about Neurocrine Biosciences Inc stockMarket Depth Overview & Small Budget Big Profits - earlytimes.in
Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments - Investing.com
Neurocrine study highlights differences between tardive dyskinesia drugs - StreetInsider
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules - PR Newswire
How Neurocrine Biosciences Inc. stock reacts to bond yieldsFed Meeting & Weekly Momentum Picks - newser.com
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BENEVICH ERIC | Chief Commercial Officer |
Nov 28 '25 |
Option Exercise |
35.99 |
5,970 |
214,860 |
50,863 |
| BENEVICH ERIC | Chief Commercial Officer |
Nov 28 '25 |
Sale |
151.74 |
5,970 |
905,881 |
44,893 |
| Onyia Jude | Chief Scientific Officer |
Nov 29 '25 |
Option Exercise |
0.00 |
4,426 |
0 |
18,129 |
1.06%
0.07%
자본화:
|
볼륨(24시간):